Page 37 - Read Online

Yoo et al. Hepatoma Res 2020;6:9 I http://dx.doi.org/10.20517/2394-5079.2019.49 Page 9 of 9

related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.
15. Masuzaki R, Tateishi R, Yoshida H, Yoshida H, Sato S, et al. Risk assessment of hepatocellular carcinoma in chronic hepatitis C
patients by transient elastography. J Clin Gastroenterol 2008;42:839-43.
16. Goodgame B, Shaheen NJ, Galanko J, El-Serag HB. The risk of end stage liver disease and hepatocellular carcinoma among persons
infected with hepatitis C virus: publication bias? Am J Gastroenterol 2003;98:2535-42.
17. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, et al. Risk of hepatocellular cancer in HCV patients treated with direct-
acting antiviral agents. Gastroenterology 2017;153:996-1005.e1.
18. Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, et al; Rete Sicilia Selezione Terapia HCV. Incidence of hepatocellular
carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology 2018;155:411-21.e4.
19. Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, et al. Newly diagnosed hepatocellular carcinoma in patients with
advanced hepatitis C treated with DAAs: A prospective population study. J Hepatol 2018;69:345-52.
20. Nagata H, Nakagawa M, Asahina Y, Sato A, Asano Y, et al; Ochanomizu Liver Conference Study G. Effect of interferon-based and
-free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol 2017;67:933-9.
21. Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, et al; Group ACC. Incidence of Hepatocellular Carcinoma After Direct
Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Gastroenterology 2018;155:1436-50.e6.
22. Yoo SH, Kwon JH, Nam SW, Kim HY, Kim CW, et al. Early development of de novo hepatocellular carcinoma after direct-acting
agent therapy: comparison with pegylated interferon-based therapy in chronic hepatitis C patients. J Viral Hepat 2018;25:1189-96.
23. Singer AW, Reddy KR, Telep LE, Osinusi AO, Brainard DM, et al. Direct-acting antiviral treatment for hepatitis C virus infection and
risk of incident liver cancer: a retrospective cohort study. Aliment Pharmacol Ther 2018;47:1278-87.
24. Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, et al; French ACOHc. Clinical outcomes in patients with chronic hepatitis C
after direct-acting antiviral treatment: a prospective cohort study. Lancet 2019;393:1453-64.
25. Ide T, Koga H, Nakano M, Hashimoto S, Yatsuhashi H, et al. Direct-acting antiviral agents do not increase the incidence of
hepatocellular carcinoma development: a prospective, multicenter study. Hepatol Int 2019;13:293-301.
26. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular
carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002;235:373-82.
27. Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and
prognosis. Ann Surg 2015;261:947-55.
28. Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, et al. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma
(HCC): a meta-regression approach. J Hepatol 2010;52:889-94.
29. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after
complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer.
Hepatology 2000;32:228-32.
30. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, et al. Effects of long-term postoperative interferon-alpha therapy on
intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern
Med 2001;134:963-7.
31. Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, et al. Prospective randomized controlled study of interferon-alpha in preventing
hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004;100:376-82.
32. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, et al; Force HCCIT. Prevention of hepatocellular carcinoma recurrence
with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006;44:1543-54.
33. ANRS collaborative study group on hepatocellular carcinoma. Lack of evidence of an effect of direct-acting antivirals on the
recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol 2016;65:734-40.
34. Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavo MR, et al; Rete Sicilia Selezione Terapia HCV. Is early recurrence of
hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre
study. Aliment Pharmacol Ther 2017;46:688-95.
35. Nishibatake Kinoshita M, Minami T, Tateishi R, Wake T, Nakagomi R, et al. Impact of direct-acting antivirals on early recurrence of
HCV-related HCC: comparison with interferon-based therapy. J Hepatol 2019;70:78-86.
36. Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV
therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol 2017;67:1204-12.
37. Singal AG, Rich NE, Mehta N, Branch A, Pillai A, et al. Direct-Acting Antiviral Therapy Not Associated With Recurrence of
Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology 2019;156:1683-92.e1.
38. Kanda T, Lau GKK, Wei L, Moriyama M, Yu ML, et al. APASL HCV guidelines of virus-eradicated patients by DAA on how to
monitor HCC occurrence and HBV reactivation. Hepatol Int 2019;13:649-61.
39. Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, et al. Cure with Interferon Free DAA is Associated with Increased Survival in Patients
with HCV related HCC from both East and West. Hepatology 201910.1002/hep.30988.
40. Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, et al; UK HCVR. Outcomes after successful direct-acting antiviral
therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;65:741-7.
41. Hanafy AS, Bassiony MA, Basha MAA. Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents:
who should be treated? Hepatol Int 2019;13:165-72.
42. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular
carcinoma. J Hepatol 2018;1:25-32.